OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

医学 贝里穆马布 狼疮性肾炎 肾功能 临床终点 内科学 安慰剂 析因分析 肌酐 泌尿科 系统性红斑狼疮 蛋白尿 胃肠病学 临床试验 肾 免疫学 疾病 病理 抗体 替代医学 B细胞 B细胞激活因子
作者
Richard Furie,Brad H. Rovin,F. Houssiau,Zahir Amoura,Mittermayer Barreto Santiago,Gabriel Contreras,Ana Malvar,Chi Chiu Mok,Amit Saxena,Xueqing Yu,Y K Onno Teng,Carly Barnett,Susan W. Burriss,Y. Green,Beulah Ji,C. Kleoudis,David A. Roth
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:79: 103-103 被引量:15
标识
DOI:10.1136/annrheumdis-2020-eular.3881
摘要

Background: Lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), affects nearly 70% of patients (pts) in high-risk groups. To preserve renal function, LN requires fast and effective treatment. Despite medical advances, progression rates at 15 years to end-stage renal disease (ESRD) remain >40% for pts with diffuse proliferative LN. Belimumab (BEL), approved in pts aged ≥5 years with active SLE, improved renal parameters in pts with baseline renal involvement in a post hoc analysis of Phase 3 trials data. Objectives: To assess efficacy and safety of intravenous (IV) BEL vs placebo (PBO), plus standard therapy (ST), in pts with active LN. Methods: BLISS-LN is a Phase 3, randomised, double-blind, PBO-controlled, 104-week study (GSK Study BEL114054, NCT01639339 ). Adults with SLE and biopsy-proven LN (class III, IV, and/or V) were randomised (1:1) to monthly BEL 10 mg/kg IV or PBO, plus ST. Primary endpoint: Primary Efficacy Renal Response (PERR); defined as urine protein creatinine ratio [uPCR] ≤0.7; estimated glomerular filtration rate [eGFR] within 20% of the pre-flare value or ≥60 ml/min/1.73m 2 ; no rescue therapy) at Week (Wk) 104. Key secondary endpoints: Complete Renal Response (CRR; defined as uPCR <0.5; eGFR within 10% of the pre-flare value or ≥90 ml/min/1.73m 2 ; no rescue therapy) at Wk 104; PERR at Wk 52; time to renal-related event (defined as ESRD/doubling of serum creatinine/renal worsening/renal disease-related treatment failure) or death. Other endpoints: time to PERR/CRR sustained through Wk 104; SLEDAI-S2K score <4 points at Wk 104; safety. Results: Overall, 448 pts were randomised (efficacy: 223/group; safety: 224/group). Significantly more BEL (43%) than PBO (32.3%) pts achieved PERR at Wk 104 (OR 1.55, 95% CI 1.04, 2.32; p=0.0311). More BEL than PBO pts achieved key secondary and other efficacy endpoints (Table). Overall, 214 (95.5%) BEL and 211 (94.2%) PBO pts had ≥1 adverse event (AE); 58 (25.9%) BEL and 67 (29.9%) PBO pts had ≥1 serious AE; 29 (12.9%) pts in each group had ≥1 AE resulting in study treatment discontinuation; 4 (1.8%) BEL and 3 (1.3%) PBO pts developed on-treatment fatal AEs. Conclusion: In the largest LN study to date, data from BLISS-LN demonstrate that BEL plus ST significantly improves LN renal responses compared with ST alone with a favourable safety profile. Study funding: GSK. Table. Endpoint, n (%) PBO (n=223) BEL (n=223) OR/HR (95% CI) vs PBO p-value CRR at Wk 104* 44 (19.7) 67 (30.0) OR 1.74 (1.11, 2.74) 0.0167 PERR at Wk 52* 79 (35.4) 104 (46.6) OR 1.59 (1.06, 2.38) 0.0245 Time to PERR through Wk 104 † 72 (32.3) 96 (43.0) HR 1.46 (1.07, 1.98) 0.0157 Time to CRR through Wk 104 † 44 (19.7) 67 (30.0) HR 1.58 (1.08, 2.31) 0.0189 Time to renal-related event or death † 63 (28.3) 35 (15.7) HR 0.51 (0.34, 0.77) 0.0014 SLEDAI-S2K score <4 points at Wk 104* 41 (18.4) 62 (27.8) OR 1.76 (1.11, 2.78) 0.0164 *PBO and BEL columns represent the n (%) responders † Data presented as n (cumulative incidence) Disclosure of Interests: Richard Furie Grant/research support from: GSK, Consultant of: GSK, Brad H Rovin Grant/research support from: GSK, Consultant of: GSK, Frederic Houssiau Grant/research support from: UCB, Consultant of: GSK, Zahir Amoura Grant/research support from: GSK, Roche, Consultant of: GSK, Astra Zeneca, Amgen, Mittermayer Santiago: None declared, Gabriel Contreras Grant/research support from: Genentech, Merck, Consultant of: Genentech, Merck, Ana Malvar Consultant of: GSK and Roche, chi chiu mok: None declared, Amit Saxena Consultant of: GSK, AZ, BMS, Xueqing Yu: None declared, Y.K. Onno Teng Grant/research support from: GSK, Consultant of: GSK, Aurinia Pharmaceuticals, Novartis, Carly Barnett Shareholder of: GSK, Employee of: GSK, Susan Burriss Shareholder of: GSK, Employee of: GSK, Yulia Green Shareholder of: GSK, Employee of: GSK, Beulah Ji Shareholder of: GSK, Employee of: GSK, Christi Kleoudis Shareholder of: GSK, Consultant of: GSK, Employee of: Parexel, David Roth Shareholder of: GSK, Employee of: GSK
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Waitcy发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
NexusExplorer的应助被iuuu采纳,获得10
3秒前
盗墓贼完成签到,获得积分10
3秒前
3秒前
英姑的应助被zzl采纳,获得10
4秒前
xiangnan发布了新的文献求助10
4秒前
5秒前
开放芯发布了新的文献求助10
6秒前
杨羽发布了新的文献求助10
6秒前
zizi不倦完成签到 ,获得积分10
6秒前
6秒前
Zikc完成签到,获得积分10
7秒前
7秒前
英俊的铭的应助被四仰化三铁采纳,获得10
8秒前
洁净山柏发布了新的文献求助30
9秒前
方暂暗完成签到,获得积分10
9秒前
雾散发布了新的文献求助10
10秒前
11秒前
11秒前
ding的应助被LIN采纳,获得30
12秒前
情怀的应助被玉玉玉米采纳,获得10
12秒前
13秒前
还等雨落的应助被MG采纳,获得10
13秒前
13秒前
xLi发布了新的文献求助10
14秒前
无私代芹完成签到,获得积分10
14秒前
14秒前
三拾壹完成签到 ,获得积分10
15秒前
taipingyang发布了新的文献求助10
16秒前
16秒前
杨羽完成签到,获得积分10
17秒前
tom发布了新的文献求助10
17秒前
流浪文献完成签到,获得积分10
17秒前
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264